{"entity":{"type":"insider","cik":"0001882764","url":"/insider/0001882764","json_url":"/insider/0001882764.json","name":"Hohl Benjamin","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":64,"n_filings":39,"first":"2023-12-27","last":"2026-08-19","span_basis":"filed_date"},"name_variants":[{"name":"Hohl Benjamin","source":"filing","n_filings":39,"first_seen":"2023-12-27","last_seen":"2026-08-19"}],"transactions":[{"id":9298772,"accession":"0001882764-26-000007","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001882764-26-000007","line_url":"/filing/0001882764-26-000007","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001882764","owner_name":"Hohl Benjamin","owner_display_name":"Hohl Benjamin","owner_url":"/insider/0001882764","role":"Officer (CHIEF FINANCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF FINANCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF FINANCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6018.0,"shares_display":"6,018","price_per_share":58.58277962778332,"price_display":"58.58","price_state":"stated","total_value":352551.1678,"total_display":"352,551.17","total_whole":"352,551","shares_owned_after":40036.0,"shares_owned_after_display":"40,036","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-08-17","filed_date":"2026-08-19","scope":"insider","n_lines":2},{"id":5924716,"accession":"0001882764-26-000006","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001882764-26-000006","line_url":"/filing/0001882764-26-000006","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001882764","owner_name":"Hohl Benjamin","owner_display_name":"Hohl Benjamin","owner_url":"/insider/0001882764","role":"Officer (CHIEF FINANCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF FINANCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF FINANCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6018.0,"shares_display":"6,018","price_per_share":52.63880500166168,"price_display":"52.64","price_state":"stated","total_value":316780.3285,"total_display":"316,780.33","total_whole":"316,780","shares_owned_after":46177.0,"shares_owned_after_display":"46,177","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-07-17","filed_date":"2026-07-21","scope":"insider","n_lines":5},{"id":5924703,"accession":"0001882764-26-000005","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001882764-26-000005","line_url":"/filing/0001882764-26-000005","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001882764","owner_name":"Hohl Benjamin","owner_display_name":"Hohl Benjamin","owner_url":"/insider/0001882764","role":"Officer (CHIEF FINANCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF FINANCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF FINANCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6018.0,"shares_display":"6,018","price_per_share":43.79816274509804,"price_display":"43.80","price_state":"stated","total_value":263577.3434,"total_display":"263,577.34","total_whole":"263,577","shares_owned_after":52238.0,"shares_owned_after_display":"52,238","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-06-17","filed_date":"2026-06-22","scope":"insider","n_lines":3},{"id":5902309,"accession":"0001882764-26-000002","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001882764-26-000002","line_url":"/filing/0001882764-26-000002#line-1","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001882764","owner_name":"Hohl Benjamin","owner_display_name":"Hohl Benjamin","owner_url":"/insider/0001882764","role":"Officer (CHIEF FINANCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF FINANCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF FINANCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":29.5839,"price_display":"29.58","price_state":"stated","total_value":295839.0,"total_display":"295,839.00","total_whole":"295,839","shares_owned_after":51000.0,"shares_owned_after_display":"51,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-03-06","filed_date":"2026-03-10","scope":"insider"},{"id":5135020,"accession":"0001882764-25-000004","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001882764-25-000004","line_url":"/filing/0001882764-25-000004#line-2","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001882764","owner_name":"Hohl Benjamin","owner_display_name":"Hohl Benjamin","owner_url":"/insider/0001882764","role":"Officer (CHIEF FINANCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF FINANCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF FINANCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3250.0,"shares_display":"3,250","price_per_share":20.3973,"price_display":"20.40","price_state":"stated","total_value":66291.225,"total_display":"66,291.22","total_whole":"66,291","shares_owned_after":23000.0,"shares_owned_after_display":"23,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-09-29","filed_date":"2025-10-01","scope":"insider"},{"id":4212067,"accession":"0001415889-25-023310","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-25-023310","line_url":"/filing/0001415889-25-023310#line-2","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001882764","owner_name":"Hohl Benjamin","owner_display_name":"Hohl Benjamin","owner_url":"/insider/0001882764","role":"Officer (CHIEF FINANCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF FINANCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF FINANCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3250.0,"shares_display":"3,250","price_per_share":20.6273,"price_display":"20.63","price_state":"stated","total_value":67038.725,"total_display":"67,038.72","total_whole":"67,039","shares_owned_after":23000.0,"shares_owned_after_display":"23,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-08-27","filed_date":"2025-08-29","scope":"insider"},{"id":4146907,"accession":"0001415889-25-020605","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001415889-25-020605","line_url":"/filing/0001415889-25-020605","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001882764","owner_name":"Hohl Benjamin","owner_display_name":"Hohl Benjamin","owner_url":"/insider/0001882764","role":"Officer (CHIEF FINANCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF FINANCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF FINANCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3250.0,"shares_display":"3,250","price_per_share":20.462694,"price_display":"20.46","price_state":"stated","total_value":66503.7555,"total_display":"66,503.76","total_whole":"66,504","shares_owned_after":23065.0,"shares_owned_after_display":"23,065","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-07-28","filed_date":"2025-07-30","scope":"insider","n_lines":2},{"id":4109559,"accession":"0001415889-25-019730","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-25-019730","line_url":"/filing/0001415889-25-019730#line-2","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001882764","owner_name":"Hohl Benjamin","owner_display_name":"Hohl Benjamin","owner_url":"/insider/0001882764","role":"Officer (CHIEF FINANCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF FINANCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF FINANCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1000.0,"shares_display":"1,000","price_per_share":22.655,"price_display":"22.66","price_state":"stated","total_value":22655.0,"total_display":"22,655.00","total_whole":"22,655","shares_owned_after":23000.0,"shares_owned_after_display":"23,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-07-10","filed_date":"2025-07-14","scope":"insider"},{"id":4176266,"accession":"0001415889-25-018718","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001415889-25-018718","line_url":"/filing/0001415889-25-018718","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001882764","owner_name":"Hohl Benjamin","owner_display_name":"Hohl Benjamin","owner_url":"/insider/0001882764","role":"Officer (CHIEF FINANCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF FINANCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF FINANCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3250.0,"shares_display":"3,250","price_per_share":20.90948006153846,"price_display":"20.91","price_state":"stated","total_value":67955.8102,"total_display":"67,955.81","total_whole":"67,956","shares_owned_after":23198.0,"shares_owned_after_display":"23,198","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-06-27","filed_date":"2025-07-01","scope":"insider","n_lines":2},{"id":4770659,"accession":"0001415889-25-017532","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-25-017532","line_url":"/filing/0001415889-25-017532#line-2","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001882764","owner_name":"Hohl Benjamin","owner_display_name":"Hohl Benjamin","owner_url":"/insider/0001882764","role":"Officer (CHIEF FINANCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF FINANCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF FINANCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3000.0,"shares_display":"3,000","price_per_share":22.5518,"price_display":"22.55","price_state":"stated","total_value":67655.4,"total_display":"67,655.40","total_whole":"67,655","shares_owned_after":23000.0,"shares_owned_after_display":"23,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-06-13","filed_date":"2025-06-17","scope":"insider"},{"id":4467225,"accession":"0001415889-25-014913","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-25-014913","line_url":"/filing/0001415889-25-014913#line-2","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001882764","owner_name":"Hohl Benjamin","owner_display_name":"Hohl Benjamin","owner_url":"/insider/0001882764","role":"Officer (CHIEF FINANCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF FINANCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF FINANCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3250.0,"shares_display":"3,250","price_per_share":16.1826,"price_display":"16.18","price_state":"stated","total_value":52593.45,"total_display":"52,593.45","total_whole":"52,593","shares_owned_after":23000.0,"shares_owned_after_display":"23,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-05-27","filed_date":"2025-05-29","scope":"insider"},{"id":4952378,"accession":"0001415889-25-011596","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001415889-25-011596","line_url":"/filing/0001415889-25-011596","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001882764","owner_name":"Hohl Benjamin","owner_display_name":"Hohl Benjamin","owner_url":"/insider/0001882764","role":"Officer (CHIEF FINANCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF FINANCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF FINANCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3250.0,"shares_display":"3,250","price_per_share":18.688477846153845,"price_display":"18.69","price_state":"stated","total_value":60737.553,"total_display":"60,737.55","total_whole":"60,738","shares_owned_after":23069.0,"shares_owned_after_display":"23,069","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-04-28","filed_date":"2025-04-30","scope":"insider","n_lines":2},{"id":5038926,"accession":"0001415889-25-009301","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-25-009301","line_url":"/filing/0001415889-25-009301#line-2","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001882764","owner_name":"Hohl Benjamin","owner_display_name":"Hohl Benjamin","owner_url":"/insider/0001882764","role":"Officer (CHIEF FINANCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF FINANCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF FINANCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3250.0,"shares_display":"3,250","price_per_share":21.3295,"price_display":"21.33","price_state":"stated","total_value":69320.875,"total_display":"69,320.88","total_whole":"69,321","shares_owned_after":23000.0,"shares_owned_after_display":"23,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-03-27","filed_date":"2025-03-31","scope":"insider"},{"id":4556183,"accession":"0001415889-25-009066","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-25-009066","line_url":"/filing/0001415889-25-009066#line-2","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001882764","owner_name":"Hohl Benjamin","owner_display_name":"Hohl Benjamin","owner_url":"/insider/0001882764","role":"Officer (CHIEF FINANCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF FINANCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF FINANCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1000.0,"shares_display":"1,000","price_per_share":22.5045,"price_display":"22.50","price_state":"stated","total_value":22504.5,"total_display":"22,504.50","total_whole":"22,505","shares_owned_after":23000.0,"shares_owned_after_display":"23,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-03-24","filed_date":"2025-03-26","scope":"insider"},{"id":4919311,"accession":"0001415889-25-006296","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-25-006296","line_url":"/filing/0001415889-25-006296#line-2","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001882764","owner_name":"Hohl Benjamin","owner_display_name":"Hohl Benjamin","owner_url":"/insider/0001882764","role":"Officer (CHIEF FINANCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF FINANCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF FINANCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3250.0,"shares_display":"3,250","price_per_share":20.4083,"price_display":"20.41","price_state":"stated","total_value":66326.975,"total_display":"66,326.98","total_whole":"66,327","shares_owned_after":13000.0,"shares_owned_after_display":"13,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-02-27","filed_date":"2025-03-03","scope":"insider"},{"id":4951470,"accession":"0001415889-25-003405","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-25-003405","line_url":"/filing/0001415889-25-003405#line-2","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001882764","owner_name":"Hohl Benjamin","owner_display_name":"Hohl Benjamin","owner_url":"/insider/0001882764","role":"Officer (CHIEF FINANCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF FINANCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF FINANCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1000.0,"shares_display":"1,000","price_per_share":22.5244,"price_display":"22.52","price_state":"stated","total_value":22524.4,"total_display":"22,524.40","total_whole":"22,524","shares_owned_after":13000.0,"shares_owned_after_display":"13,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-02-05","filed_date":"2025-02-07","scope":"insider"},{"id":4500028,"accession":"0001415889-25-002298","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-25-002298","line_url":"/filing/0001415889-25-002298#line-2","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001882764","owner_name":"Hohl Benjamin","owner_display_name":"Hohl Benjamin","owner_url":"/insider/0001882764","role":"Officer (CHIEF FINANCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF FINANCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF FINANCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3250.0,"shares_display":"3,250","price_per_share":21.5932,"price_display":"21.59","price_state":"stated","total_value":70177.9,"total_display":"70,177.90","total_whole":"70,178","shares_owned_after":13000.0,"shares_owned_after_display":"13,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-01-27","filed_date":"2025-01-29","scope":"insider"},{"id":5152676,"accession":"0001415889-25-001007","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001415889-25-001007","line_url":"/filing/0001415889-25-001007#line-3","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001882764","owner_name":"Hohl Benjamin","owner_display_name":"Hohl Benjamin","owner_url":"/insider/0001882764","role":"Officer (CHIEF FINANCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF FINANCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF FINANCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1000.0,"shares_display":"1,000","price_per_share":25.0386,"price_display":"25.04","price_state":"stated","total_value":25038.6,"total_display":"25,038.60","total_whole":"25,039","shares_owned_after":13000.0,"shares_owned_after_display":"13,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-01-03","filed_date":"2025-01-07","scope":"insider"},{"id":2605328,"accession":"0001415889-24-030323","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001415889-24-030323","line_url":"/filing/0001415889-24-030323#line-4","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001882764","owner_name":"Hohl Benjamin","owner_display_name":"Hohl Benjamin","owner_url":"/insider/0001882764","role":"Officer (CHIEF FINANCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF FINANCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF FINANCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":900.0,"shares_display":"900","price_per_share":22.5061,"price_display":"22.51","price_state":"stated","total_value":20255.49,"total_display":"20,255.49","total_whole":"20,255","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-12-30","filed_date":"2024-12-31","scope":"insider"},{"id":2605309,"accession":"0001415889-24-030323","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-030323","line_url":"/filing/0001415889-24-030323#line-2","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001882764","owner_name":"Hohl Benjamin","owner_display_name":"Hohl Benjamin","owner_url":"/insider/0001882764","role":"Officer (CHIEF FINANCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF FINANCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF FINANCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3350.0,"shares_display":"3,350","price_per_share":22.1549,"price_display":"22.15","price_state":"stated","total_value":74218.915,"total_display":"74,218.92","total_whole":"74,219","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-12-27","filed_date":"2024-12-31","scope":"insider"},{"id":2044427,"accession":"0001415889-24-028001","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001415889-24-028001","line_url":"/filing/0001415889-24-028001","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001882764","owner_name":"Hohl Benjamin","owner_display_name":"Hohl Benjamin","owner_url":"/insider/0001882764","role":"Officer (CHIEF FINANCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF FINANCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF FINANCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5250.0,"shares_display":"5,250","price_per_share":24.89302380952381,"price_display":"24.89","price_state":"stated","total_value":130688.375,"total_display":"130,688.38","total_whole":"130,688","shares_owned_after":1000.0,"shares_owned_after_display":"1,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-11-27","filed_date":"2024-12-02","scope":"insider","n_lines":2},{"id":2604646,"accession":"0001415889-24-025779","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001415889-24-025779","line_url":"/filing/0001415889-24-025779","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001882764","owner_name":"Hohl Benjamin","owner_display_name":"Hohl Benjamin","owner_url":"/insider/0001882764","role":"Officer (CHIEF FINANCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF FINANCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF FINANCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6250.0,"shares_display":"6,250","price_per_share":28.5575408,"price_display":"28.56","price_state":"stated","total_value":178484.63,"total_display":"178,484.63","total_whole":"178,485","shares_owned_after":650.0,"shares_owned_after_display":"650","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-10-28","filed_date":"2024-10-30","scope":"insider","n_lines":2},{"id":2449027,"accession":"0001415889-24-025501","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-025501","line_url":"/filing/0001415889-24-025501#line-2","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001882764","owner_name":"Hohl Benjamin","owner_display_name":"Hohl Benjamin","owner_url":"/insider/0001882764","role":"Officer (CHIEF FINANCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF FINANCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF FINANCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":814.0,"shares_display":"814","price_per_share":30.003,"price_display":"30.00","price_state":"stated","total_value":24422.442,"total_display":"24,422.44","total_whole":"24,422","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-10-18","filed_date":"2024-10-22","scope":"insider"},{"id":2448932,"accession":"0001415889-24-024900","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001415889-24-024900","line_url":"/filing/0001415889-24-024900#line-4","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001882764","owner_name":"Hohl Benjamin","owner_display_name":"Hohl Benjamin","owner_url":"/insider/0001882764","role":"Officer (CHIEF FINANCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF FINANCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF FINANCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1270.0,"shares_display":"1,270","price_per_share":27.5081,"price_display":"27.51","price_state":"stated","total_value":34935.287,"total_display":"34,935.29","total_whole":"34,935","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-10-07","filed_date":"2024-10-08","scope":"insider"},{"id":2448926,"accession":"0001415889-24-024900","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-024900","line_url":"/filing/0001415889-24-024900#line-2","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001882764","owner_name":"Hohl Benjamin","owner_display_name":"Hohl Benjamin","owner_url":"/insider/0001882764","role":"Officer (CHIEF FINANCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF FINANCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF FINANCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10218.0,"shares_display":"10,218","price_per_share":27.5082,"price_display":"27.51","price_state":"stated","total_value":281078.7876,"total_display":"281,078.79","total_whole":"281,079","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-10-04","filed_date":"2024-10-08","scope":"insider"},{"id":2486258,"accession":"0001415889-24-024669","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-024669","line_url":"/filing/0001415889-24-024669#line-2","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001882764","owner_name":"Hohl Benjamin","owner_display_name":"Hohl Benjamin","owner_url":"/insider/0001882764","role":"Officer (CHIEF FINANCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF FINANCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF FINANCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":521.0,"shares_display":"521","price_per_share":27.5372,"price_display":"27.54","price_state":"stated","total_value":14346.8812,"total_display":"14,346.88","total_whole":"14,347","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-10-01","filed_date":"2024-10-03","scope":"insider"},{"id":2448845,"accession":"0001415889-24-024249","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001415889-24-024249","line_url":"/filing/0001415889-24-024249#line-4","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001882764","owner_name":"Hohl Benjamin","owner_display_name":"Hohl Benjamin","owner_url":"/insider/0001882764","role":"Officer (CHIEF FINANCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF FINANCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF FINANCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2000.0,"shares_display":"2,000","price_per_share":25.3338,"price_display":"25.33","price_state":"stated","total_value":50667.6,"total_display":"50,667.60","total_whole":"50,668","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-09-30","filed_date":"2024-10-01","scope":"insider"},{"id":2448835,"accession":"0001415889-24-024249","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-024249","line_url":"/filing/0001415889-24-024249#line-2","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001882764","owner_name":"Hohl Benjamin","owner_display_name":"Hohl Benjamin","owner_url":"/insider/0001882764","role":"Officer (CHIEF FINANCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF FINANCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF FINANCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4250.0,"shares_display":"4,250","price_per_share":24.2732,"price_display":"24.27","price_state":"stated","total_value":103161.1,"total_display":"103,161.10","total_whole":"103,161","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-09-27","filed_date":"2024-10-01","scope":"insider"},{"id":3237424,"accession":"0001415889-24-022589","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-022589","line_url":"/filing/0001415889-24-022589#line-2","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001882764","owner_name":"Hohl Benjamin","owner_display_name":"Hohl Benjamin","owner_url":"/insider/0001882764","role":"Officer (CHIEF FINANCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF FINANCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF FINANCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4250.0,"shares_display":"4,250","price_per_share":22.5369,"price_display":"22.54","price_state":"stated","total_value":95781.825,"total_display":"95,781.82","total_whole":"95,782","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-08-27","filed_date":"2024-08-29","scope":"insider"},{"id":3177727,"accession":"0001415889-24-020686","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-020686","line_url":"/filing/0001415889-24-020686#line-2","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001882764","owner_name":"Hohl Benjamin","owner_display_name":"Hohl Benjamin","owner_url":"/insider/0001882764","role":"Officer (CHIEF FINANCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF FINANCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF FINANCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":991.0,"shares_display":"991","price_per_share":27.5287,"price_display":"27.53","price_state":"stated","total_value":27280.9417,"total_display":"27,280.94","total_whole":"27,281","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-07-31","filed_date":"2024-08-02","scope":"insider"},{"id":2603855,"accession":"0001415889-24-020475","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001415889-24-020475","line_url":"/filing/0001415889-24-020475","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001882764","owner_name":"Hohl Benjamin","owner_display_name":"Hohl Benjamin","owner_url":"/insider/0001882764","role":"Officer (CHIEF FINANCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF FINANCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF FINANCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5250.0,"shares_display":"5,250","price_per_share":26.676610571428572,"price_display":"26.68","price_state":"stated","total_value":140052.2055,"total_display":"140,052.21","total_whole":"140,052","shares_owned_after":61.0,"shares_owned_after_display":"61","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-07-29","filed_date":"2024-07-31","scope":"insider","n_lines":2},{"id":2101691,"accession":"0001415889-24-019598","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-019598","line_url":"/filing/0001415889-24-019598#line-2","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001882764","owner_name":"Hohl Benjamin","owner_display_name":"Hohl Benjamin","owner_url":"/insider/0001882764","role":"Officer (CHIEF FINANCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF FINANCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF FINANCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3000.0,"shares_display":"3,000","price_per_share":25.065,"price_display":"25.06","price_state":"stated","total_value":75195.0,"total_display":"75,195.00","total_whole":"75,195","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-07-12","filed_date":"2024-07-16","scope":"insider"},{"id":2755827,"accession":"0001415889-24-018694","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001415889-24-018694","line_url":"/filing/0001415889-24-018694","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001882764","owner_name":"Hohl Benjamin","owner_display_name":"Hohl Benjamin","owner_url":"/insider/0001882764","role":"Officer (CHIEF FINANCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF FINANCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF FINANCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4250.0,"shares_display":"4,250","price_per_share":22.569776,"price_display":"22.57","price_state":"stated","total_value":95921.548,"total_display":"95,921.55","total_whole":"95,922","shares_owned_after":1140.0,"shares_owned_after_display":"1,140","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-06-27","filed_date":"2024-07-01","scope":"insider","n_lines":3},{"id":2189919,"accession":"0001415889-24-014914","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001415889-24-014914","line_url":"/filing/0001415889-24-014914#line-4","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001882764","owner_name":"Hohl Benjamin","owner_display_name":"Hohl Benjamin","owner_url":"/insider/0001882764","role":"Officer (CHIEF FINANCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF FINANCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF FINANCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2334.0,"shares_display":"2,334","price_per_share":23.4184,"price_display":"23.42","price_state":"stated","total_value":54658.5456,"total_display":"54,658.55","total_whole":"54,659","shares_owned_after":10.0,"shares_owned_after_display":"10","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-05-28","filed_date":"2024-05-30","scope":"insider"},{"id":2189916,"accession":"0001415889-24-014914","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001415889-24-014914","line_url":"/filing/0001415889-24-014914#line-3","is_derivative":false,"issuer_cik":"0001672619","issuer_name":"Enliven Therapeutics, Inc.","issuer_ticker":"ELVN","issuer_name_source":null,"issuer_url":"/issuer/0001672619","owner_cik":"0001882764","owner_name":"Hohl Benjamin","owner_display_name":"Hohl Benjamin","owner_url":"/insider/0001882764","role":"Officer (CHIEF FINANCIAL OFFICER)","role_mark":"O","role_mark_label":"Officer (CHIEF FINANCIAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CHIEF FINANCIAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1906.0,"shares_display":"1,906","price_per_share":22.89,"price_display":"22.89","price_state":"stated","total_value":43628.34,"total_display":"43,628.34","total_whole":"43,628","shares_owned_after":2344.0,"shares_owned_after_display":"2,344","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-05-28","filed_date":"2024-05-30","scope":"insider"}],"collapsed":true,"next_cursor":"2024-05-28|2189916","ledger_fault":false,"count":{"value":64,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":64,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":64},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001672619","name":"Enliven Therapeutics, Inc.","url":"/issuer/0001672619","role":"Officer (CHIEF FINANCIAL OFFICER)","n_filings":39,"first_seen":"2023-12-27","last_seen":"2026-08-19"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001882764","retrieved_at":"2026-08-25T17:22:20+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-24","last_ingest":"2026-08-25T05:24:19.374141+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}